MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from a large Phase III clinical study of ciclesonide nasal aerosol, a corticosteroid formulated with a hydrofluoroalkane (HFA) propellant, intended for the treatment of allergic rhinitis. This 26 week, double-blind, randomized study, investigated 74 mcg or 148 mcg doses of ciclesonide nasal aerosol once-daily in 1,111 patients, 12 years of age and older with perennial allergic rhinitis (PAR). Statistically significant improvements in nasal symptoms were demonstrated in patients with PAR compared to placebo, after the first six weeks of double-blind treatment, for both the 74 mcg and 148 mcg doses. Results from the full 26 week, double-blind treatment period demonstrated tolerability of both the 74 mcg and 148 mcg doses of ciclesonide nasal aerosol compared to placebo. Data from the first six weeks of treatment as well as the full six months of study treatment were presented in four separate scientific posters at the 2011 annual meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Boston, Massachusetts.
